Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DFV890 for Inflammatory Marker Reduction in Adult Participants With Coronary Heart Disease and Elevated hsCRP
NCT06031844Phase 2Completed
- Sponsor
- Novartis
- Start
- Oct 2023
- Primary completion
- Dec 2024
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 2, randomised, double-blind trial of DFV890 in coronary heart disease (CHD) (4 arms), sponsored by Novartis. Primary endpoints: Ratio to Baseline Serum Levels of IL-6 for DFV890 Based on an Emax Model and Ratio to Baseline Serum Levels of IL-18 for DFV890 Based on an Emax Model. Started Oct 2023; status: completed.
02
Drugs
DFV890
03
Conditions
coronary heart disease (CHD)
Beyond the preview
Go deeper on NCT06031844.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06031844.